PMID- 27772741
OWN - NLM
STAT- MEDLINE
DCOM- 20170612
LR  - 20170916
IS  - 1878-5883 (Electronic)
IS  - 0022-510X (Linking)
VI  - 370
DP  - 2016 Nov 15
TI  - Decreased risk of cancer in multiple sclerosis patients and analysis of the
      effect of disease modifying therapies on cancer risk.
PG  - 13-17
LID - S0022-510X(16)30564-0 [pii]
LID - 10.1016/j.jns.2016.09.005 [doi]
AB  - BACKGROUND: Although dysimmunity is considered an important link between multiple
      sclerosis (MS), family history and cancer risk, their relationship to the use of 
      disease modifying therapies (DMT) is not fully understood. OBJECTIVE: To assess
      the observed versus expected number of cancers in MS patients, and family history
      of cancer, among DMT users and DMT naive patients. METHODS: Cancer, DMT use, and 
      family history of cancer were assessed using the New York State Multiple
      Sclerosis Consortium (NYSMSC) registry. Self-reported cancers in MS patients were
      tested for associations with DMT use, family history of cancer and other factors.
      Expected number of cancer cases was estimated using age- and gender-specific
      prevalence and incidence rates from the general population. RESULTS: The
      prevalence of cancer in males and females in the NYSMSC cohort was lower than
      expected (p<0.001). Patients with cancer were older at MS diagnosis and more
      likely to be female (p<0.001). MS patients with a personal history of cancer were
      more likely to report DMT use (p<0.001) and family history of cancer (p<0.001).
      Multivariable analysis did not support a higher risk of cancer after DMT
      initiation. CONCLUSIONS: We report a lower than expected number of cancer cases
      in MS patients compared to the general population. MS patients with a personal
      history of cancer were more likely to report DMT use suggesting that DMTs may
      abrogate the lower incidence of cancer in MS.
CI  - Copyright (c) 2016 Elsevier B.V. All rights reserved.
FAU - Gaindh, Deeya
AU  - Gaindh D
AD  - Jacobs Comprehensive MS Treatment and Research Center, University at Buffalo,
      Buffalo, NY, USA.
FAU - Kavak, Katelyn S
AU  - Kavak KS
AD  - Jacobs Comprehensive MS Treatment and Research Center, University at Buffalo,
      Buffalo, NY, USA; New York State MS Consortium, University at Buffalo, Buffalo,
      NY, USA.
FAU - Teter, Barbara
AU  - Teter B
AD  - Jacobs Comprehensive MS Treatment and Research Center, University at Buffalo,
      Buffalo, NY, USA; New York State MS Consortium, University at Buffalo, Buffalo,
      NY, USA; Department of Neurology, State University of New York at Buffalo,
      Buffalo, NY, USA.
FAU - Vaughn, Caila B
AU  - Vaughn CB
AD  - Jacobs Comprehensive MS Treatment and Research Center, University at Buffalo,
      Buffalo, NY, USA; New York State MS Consortium, University at Buffalo, Buffalo,
      NY, USA; Department of Neurology, State University of New York at Buffalo,
      Buffalo, NY, USA.
FAU - Cookfair, Diane
AU  - Cookfair D
AD  - Department of Neurology, State University of New York at Buffalo, Buffalo, NY,
      USA.
FAU - Hahn, Theresa
AU  - Hahn T
AD  - Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA.
FAU - Weinstock-Guttman, Bianca
AU  - Weinstock-Guttman B
AD  - Jacobs Comprehensive MS Treatment and Research Center, University at Buffalo,
      Buffalo, NY, USA; New York State MS Consortium, University at Buffalo, Buffalo,
      NY, USA; Department of Neurology, State University of New York at Buffalo,
      Buffalo, NY, USA. Electronic address: bweinstock-guttman@kaleidahealth.org.
CN  - New York State Multiple Sclerosis Consortium
LA  - eng
PT  - Journal Article
DEP - 20160909
PL  - Netherlands
TA  - J Neurol Sci
JT  - Journal of the neurological sciences
JID - 0375403
RN  - 0 (Immunologic Factors)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Female
MH  - Follow-Up Studies
MH  - Genetic Predisposition to Disease
MH  - Humans
MH  - Immunologic Factors/*adverse effects/*therapeutic use
MH  - Incidence
MH  - Longitudinal Studies
MH  - Male
MH  - Middle Aged
MH  - Multiple Sclerosis/*drug therapy/epidemiology
MH  - Neoplasms/*epidemiology
MH  - New York/epidemiology
MH  - Prevalence
MH  - Registries
MH  - Retrospective Studies
MH  - Risk
MH  - Self Report
MH  - Young Adult
OTO - NOTNLM
OT  - Cancer
OT  - Disease modifying therapy (DMT)
OT  - Multiple sclerosis
EDAT- 2016/10/25 06:00
MHDA- 2017/06/13 06:00
CRDT- 2016/10/25 06:00
PHST- 2016/03/29 00:00 [received]
PHST- 2016/08/10 00:00 [revised]
PHST- 2016/09/06 00:00 [accepted]
PHST- 2016/10/25 06:00 [pubmed]
PHST- 2017/06/13 06:00 [medline]
PHST- 2016/10/25 06:00 [entrez]
AID - S0022-510X(16)30564-0 [pii]
AID - 10.1016/j.jns.2016.09.005 [doi]
PST - ppublish
SO  - J Neurol Sci. 2016 Nov 15;370:13-17. doi: 10.1016/j.jns.2016.09.005. Epub 2016
      Sep 9.